Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Eledon has upcoming clinical data presentations and remains on track for a major Phase 3 trial initiation in Q4 2026, providing positive momentum for the stock.
Eledon will present long-term safety and efficacy data for tegoprubart in preventing kidney transplant rejection at the International Congress of The Transplantation Society in Sydney. The presentation is scheduled for September 22, 2026, and serves as a key update on the company's lead clinical program.
Eledon Pharmaceuticals Press Release